Petrelintide

New to peptides? Start with what are peptides? and how do peptides work?

Overview

Petrelintide is a long-acting analog of amylin, the hormone your pancreas releases alongside insulin to signal that a meal has arrived. It represents a specific bet in obesity medicine: that amylin can work as a standalone therapy rather than only as a partner to a GLP-1 drug, and that it can do so with markedly better tolerability than incretin drugs.

The engineering problem it solves

Human amylin is difficult to use as a drug because it aggregates — the molecules clump into fibrils, the same process implicated in beta-cell damage in type 2 diabetes. The first amylin drug, pramlintide, worked around this but required injection at every meal, which limited its uptake. Petrelintide is engineered to resist fibrillation and to remain stable in solution, which enables once-weekly dosing and, importantly, makes it a candidate for co-formulation with other agents in a single injection.

Who is developing it

Petrelintide comes from Zealand Pharma, partnered with Roche in a major 2025 collaboration. It is being developed both as a monotherapy and in combination with Roche's dual GLP-1/GIP agonist, so the program hedges across both strategies.

Status

It is investigational and not approved. Phase 2 is complete, and the partners announced in April 2026 that the compound would advance to Phase 3, with initiation planned for the second half of 2026. Nothing sold under this name is a legitimate product.

How it works

The amylin pathway

Amylin is co-secreted with insulin from pancreatic beta cells in response to meals. It acts on amylin receptors — calcitonin receptors paired with receptor activity-modifying proteins — concentrated in the area postrema of the brainstem, a region that sits outside the blood-brain barrier and specializes in monitoring the blood for signals about what has been eaten.

Activating this pathway does three things: it slows gastric emptying, it suppresses inappropriate glucagon release after meals, and it promotes satiety, causing meals to end sooner and reducing overall intake.

How this differs from GLP-1

Both pathways reduce food intake, but through different receptors in different brain regions, and they appear to shape eating behavior somewhat differently — amylin signaling is more closely tied to meal termination and satiation, while GLP-1 signaling also carries a strong aversive component at higher doses. That difference is the mechanistic argument for why an amylin analog might reduce weight with less nausea, and why the two classes might combine additively.

The leptin connection

Preclinical work suggests amylin signaling can restore some sensitivity to leptin, the hormone that reports on long-term fat stores and to which people with obesity typically become resistant. If this holds in humans it would mean amylin analogs act on a different layer of weight regulation than meal-by-meal appetite. This remains a hypothesis supported by animal data, not an established human effect.

Clinical evidence

ZUPREME-1

The Phase 2 ZUPREME-1 trial studied petrelintide in adults with overweight or obesity without type 2 diabetes over 42 weeks. It met its primary endpoint, with mean weight loss of up to approximately 10.7% at 42 weeks versus about 1.7% on placebo. Further analyses were presented at the American Diabetes Association meeting in June 2026.

Why tolerability is the headline, not the weight loss

Roughly 10% weight loss is meaningful but below what the leading GLP-1 and dual-agonist drugs achieve. What drew attention was the tolerability profile, reported as close to placebo for gastrointestinal side effects. That matters because real-world discontinuation of incretin drugs is high, and much of it is driven by nausea. A drug that delivers moderate weight loss that people actually stay on can outperform, in practice, a stronger drug that a large fraction of patients abandon. This is a genuine argument, but it is a hypothesis about real-world behavior that Phase 3 and post-marketing data will have to test.

ZUPREME-2 and combination work

ZUPREME-2 studies petrelintide in people with overweight or obesity and type 2 diabetes, with results expected in the second half of 2026. Separately, petrelintide is being developed in combination with Roche's dual GLP-1/GIP agonist, testing whether stacking the pathways produces greater effect.

Evidence tier

This is Phase 2 evidence — real randomized human data, but mid-stage. Phase 3 has not started as of this writing, no regulator has reviewed the drug, and long-term efficacy and safety are unestablished. Mid-stage results in obesity have repeatedly failed to hold up at scale, so enthusiasm should be calibrated accordingly.

Safety & status

What has been reported

Reported adverse events to date are predominantly gastrointestinal — mainly nausea — and were notably mild in the Phase 2 program, which is the drug's principal selling point. Injection-site reactions and the general immunogenicity questions that attend any peptide analog are also monitored.

It is important to be clear about what a favorable Phase 2 tolerability signal does and does not establish. Phase 2 trials enroll a few hundred carefully selected participants for under a year. Rare adverse events, effects in people with multiple conditions, and anything that takes years to appear are simply not detectable at that scale. The safety profile of petrelintide is best described as promising but unestablished.

Status

Petrelintide is not FDA-approved, not available by prescription, and not commercially available anywhere. It is not obtainable outside a clinical trial. Any vial sold as petrelintide by a research-chemical vendor is an unregulated product of unverified identity and purity, and the trial data above tells you nothing about what is in it.

For the broader landscape, see our guide to weight-loss peptides and the related amylin programs eloralintide and cagrilintide.

The amylin analogs compared

Amylin is released with insulin and signals fullness through the brainstem — a pathway independent of GLP-1. That independence is why this class is considered the most promising frontier after the incretin drugs, either alone or stacked with them.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Fischer Munch H, Just R, Mosolff Mathiesen J, et al. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. J Med Chem. 2025. Peer-reviewed study
2. Alhazmi A, le Roux CW. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. Diabetes Obes Metab. 2026. Peer-reviewed study
3. Bailey CJ, Flatt PR, Conlon JM. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides. 2026. Peer-reviewed study
4. Fischer Munch H, Just R, Mosolff Mathiesen J, et al.. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. J Med Chem. 2025. Peer-reviewed study
5. Bailey CJ, Flatt PR, Conlon JM. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides. 2026. Peer-reviewed study
6. Alhazmi A, le Roux CW. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. Diabetes Obes Metab. 2026. Peer-reviewed study
7. Fischer SL, Borner T. Beyond GLP-1: Amylin-Based Pharmacotherapy and the Search for Better-Tolerated Weight-Loss Drugs. Pharmacol Res. 2026. Peer-reviewed study